Lhasa Limited shared knowledge shared progress
Home > Library > Publication list per product

Publication list per product

Sarah NexusSarah Nexus Publications

The following links provide access to relevant Sarah Nexus publications for the last 2 years. If you would like to view older publications, or to refine your search criteria further please search the library.

TitlePublishedTypeProducts
Chapter 3: Control Strategies for Mutagenic ImpuritiesMarch 2022MirabilisDerek NexusSarah Nexus
Chapter 9: Mutagenic Impurities – Assessment of Fate and Control OptionsMarch 2022Derek NexusSarah NexusMirabilis
Chapter 17: Use of Lhasa Limited Products for the In Silico Prediction of Drug ToxicityFebruary 2022Derek NexusSarah NexusMirabilisZeneth
Chapter 7: Compound- and Class-Specific Limits for Common Impurities in PharmaceuticalsFebruary 2022Derek NexusSarah NexusMirabilis
How carboxylic and sulfonic acid halides are represented within Derek Nexus and Sarah NexusOctober 2021pdf fileDerek NexusSarah Nexus
In Silico Prediction of Genotoxicity Current Applications and Future PerspectivesSeptember 2021pdf fileDerek NexusSarah Nexus
Resolving conflicting data sources to a single call in Sarah Nexus [an infographic]September 2021pdf fileSarah Nexus
QSAR 2021 Addressing the global challenge of N-nitrosamine impurity assessmentJune 2021pdf fileDerek NexusMirabilisSarah NexusVitic Nexus
Predicting N-Nitrosamine Activity from SARJune 2021pdf fileDerek NexusSarah Nexus
Nexus ICH M7 Expert Review Support Functionality (an infographic)December 2020pdf fileDerek NexusSarah Nexus
Management of pharmaceutical ICH M7 (Q)SAR predictions – The impact of model updatesNovember 2020Derek NexusSarah NexusVitic Nexus
The importance of expert review to clarify ambiguous situations for (Q)SAR predictions under ICH M7September 2020Derek NexusSarah Nexus
ICH M7 Expert Review Workshop: Resolving common prediction scenarios using automated arguments in Nexus 2.3 (Webinar Presentation Slides)September 2020pdf fileDerek NexusSarah Nexus
Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity dataSeptember 2020Derek NexusSarah NexusVitic Nexus
Do all nitrosamines pose a significant level of genotoxic risk? (Webinar Presentation Slides)July 2020pdf fileDerek NexusSarah Nexus
ICH M7 Workshop Japanese ICGM 2019July 2020pdf fileSetariaSarah NexusMirabilisVitic NexusDerek Nexus
Lhasa Knowledge Suite Nexus 2.3 Release NotesJune 2020pdf fileDerek NexusSarah Nexus
Sarah Nexus Mutagenicity QMRF.pdfJune 2020pdf fileSarah Nexus
The application of in silico models to support decision making in toxicologyMay 2020pdf fileDerek NexusSetariaVitic NexusZenethMirabilisSarah Nexus
In silico workflow under ICH M7March 2020pdf fileDerek NexusSetariaVitic NexusSarah Nexus
ICH M7 Workshop - 2020 ICH M7 India RoadshowsMarch 2020pdf fileDerek NexusSarah NexusZenethVitic NexusSetariaMirabilis
Predictions, Data and ICH M7 - 2020 ICH M7 India RoadshowsMarch 2020pdf fileDerek NexusSarah NexusVitic NexusSetaria
Lhasa and the ICH M7 Guideline - 2020 ICH M7 India RoadshowMarch 2020pdf fileDerek NexusSarah NexusVitic NexusSetariaMirabilis
GSK MI risk assessment process Camicinal at al - 2020 ICH M7 India RoadshowMarch 2020pdf fileDerek NexusSarah NexusVitic Nexus
Hazard Assessment of Potentially Mutagenic Impurities - 2020 ICH M7 India RoadshowsMarch 2020pdf fileDerek NexusSarah Nexus
ICH M7 - Regulatory Updates and Industry Practices - 2020 ICH M7 India RoadshowsMarch 2020pdf fileDerek NexusSarah Nexus
Lhasa Expert Review Developments - 2020 ICH M7 India RoadshowsMarch 2020pdf fileDerek NexusSarah NexusVitic Nexus

  • Linked In
  • Twitter
  • Instagram
  • Facebook

© 2022 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Apart from the free survey software, we also have access to QuestionPro's free survey templates . We've found many of them useful and powerful to collect insights from various stakeholders of our organization.